Development and validation of a plasma-based melanoma biomarker suitable for clinical use

BACKGROUND: In Australia, more money is spent on skin cancer than any other malignancy. Despite this, the mortality rate of melanoma, the deadliest form, has steadily increased over the past 50 years. Diagnostic imprecision and a lack of complimentary molecular biomarkers are partially responsible f...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Laar, Ryan, Lincoln, Mitchel, Van Laar, Barton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886119/
https://www.ncbi.nlm.nih.gov/pubmed/29360813
http://dx.doi.org/10.1038/bjc.2017.477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886119/
https://www.ncbi.nlm.nih.gov/pubmed/29360813
http://dx.doi.org/10.1038/bjc.2017.477

Ejemplares similares